Allogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameAllogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicThrombocytopenia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicThrombocytopenia +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A